Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Fatty Liver Alliance: Advancing Awareness and Advocacy for MASLD and MASH
Steatotic Liver Disease (MASLD/MASH)
Free Liver and Metabolic Health Education Event
Meet Dr. Supriya Joshi, Hepatologist
Join us on February 3, 2025 in Mississauga, ON,
Register now at fattyliver.ca/register
Here are a Few of Our Recent Blog Posts
MASLD and MASH: Understanding the Basics: Disease Stages
MASLD and MASH: Understanding the Basics: Disease Stages
MASLD and MASH: Understanding the Basics: Disease Stages
Receiving a diagnosis of MASLD (Metabolic Associated Steatotic Liver Disease) or MASH (Metabolic Associated Steatohepatitis) can feel overwhelming, but understanding your condition is the first step toward managing it effectively.
Introduction to MASLD & MASH
MASLD and MASH: Understanding the Basics: Disease Stages
MASLD and MASH: Understanding the Basics: Disease Stages
A clear, easy-to-understand overview of MASLD and MASH, covering what these terms mean, how the liver functions, and the significance of a MASH diagnosis. With special guest, Dr. Sonal Kumar, Hepatologist.
New Year's resolution tips to improve your liver health
MASLD and MASH: Understanding the Basics: Disease Stages
New Year's resolution tips to improve your liver health
Here are some simple and effective New Year's resolution tips to improve liver health, with a focus on managing MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic dysfunction-Associated Steatohepatitis).
Top 10 MASLD/MASH Developments in 2024
7 Most Important Things Patients Need to Know About MASLD
New Year's resolution tips to improve your liver health
The year 2024 has marked significant progress in the field of MASLD and MASH, with groundbreaking advancements in diagnostics, treatments, and clinical guidelines. Here’s a concise look at the top 10 developments that are shaping the future of liver health and patient care.
7 Most Important Things Patients Need to Know About MASLD
7 Most Important Things Patients Need to Know About MASLD
7 Most Important Things Patients Need to Know About MASLD
Empowering Patients for Better Outcomes
Physicians and allied healthcare professionals play a critical role in guiding patients toward positive outcomes. By fostering open communication and building trust, they can help patients feel in control of their health and motivated to take proactive steps to manage MASLD.
Two Distinct Subtypes of MASH Found
7 Most Important Things Patients Need to Know About MASLD
7 Most Important Things Patients Need to Know About MASLD
"What we propose is we are facing not one disease called MASH, but two subtypes of the disease… They look alike when you look at the liver, but they are very different, because one is liver-specific—genetically driven—and the other is cardiometabolic, where the liver is the victim.” Professor Pattou.
Keeping it Real During the Holidays
Exercise Prescriptions to Treat MASLD for the Busy Clinician
Exercise Prescriptions to Treat MASLD for the Busy Clinician
The holiday season has arrived, and with it comes plenty of family gatherings, big meals, and all kinds of festive treats. It’s only natural to want to join in on the fun, but if you’re watching out for your liver health—maybe you’ve been diagnosed with MASLD or MASH, or you just want to make smarter choices, and sticking to healthy habits can feel tough this time of year. Here’s how to enjoy the festivities without giving your liver extra stress.
Exercise Prescriptions to Treat MASLD for the Busy Clinician
Exercise Prescriptions to Treat MASLD for the Busy Clinician
Exercise Prescriptions to Treat MASLD for the Busy Clinician
Dr. Jonathan Stine emphasizes the critical role of exercise in managing MASH and MASLD, highlighting its benefits for liver health, reducing liver fat, improving inflammation, and potentially reversing fibrosis.
Physicians should prescribe 150 minutes of moderate-intensity aerobic activity weekly, combined with resistance training, and use tools like the "Physical Activity Playbook" to guide patients. By addressing barriers and tailoring exercise prescriptions to individual needs, physicians can improve patient outcomes significantly.
Regular follow-ups and referrals to exercise professionals or digital programs can further support long-term adherence and health improvements.
What are Ultra-Processed Foods?
Exercise Prescriptions to Treat MASLD for the Busy Clinician
Uncovering the Silent Epidemic of MASLD/MASH
At the heart of healthier living is understanding what we eat. Professor Shira Zelber-Sagi and Michael Betel discuss the growing prevalence and impact of ultra-processed foods on our diets and health.
Uncovering the Silent Epidemic of MASLD/MASH
A Call to Action: Why Radiologists Must Have a Seat at the Table
Uncovering the Silent Epidemic of MASLD/MASH
Key Insights on Fatty Liver Disease (MASLD) and How You Can Help
We’re excited to share the full video of our recent presentation on fatty liver disease (MASLD) affecting over 25% of North Americans and even more globally. Dr. Alnoor Ramji shares a great overview of this serious and silent liver disease.
Many are unaware they have it, so raising awareness is crucial. Watch the video to learn more about this silent but impactful disease.
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
Why Radiologists Matter
The importance of radiology in managing MASLD and MASH cannot be overstated. Non-invasive imaging techniques, such as MRI-PDFF (Proton Density Fat Fraction) and elastography, are crucial tools in assessing liver fat content and fibrosis levels—key indicators of disease progression. Dr. Sirlin highlighted the advancements in quantitative imaging, which allow for precise measurements of liver health without the need for biopsies.
MASLD and MASH Vancouver Community Event
A Call to Action: Why Radiologists Must Have a Seat at the Table
A Call to Action: Why Radiologists Must Have a Seat at the Table
This week we will begin to share presentations and some great questions and answers about MASLD and MASH from our Vancouver community event. For today, here is a quick wrap up chat about the event - a teaser for what we will post this week.
Key take-aways include:
1. Early Diagnosis is Crucial
2. Role of Advocacy Groups
3. Multidisciplinary Approach:
4. Advancements in Diagnostic Tools
5. Public Awareness and Stigma
Urgent Call to Action
Fatty Liver Alliance in the News
The Fatty Liver Alliance a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian regulators for approval of Rezdiffra (resmetirom), the company’s oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
https://liverdiseasenews.com/news/nonprofits-petition-aims-expedite-canadian-access-rezdiffra/
Canadians Deserve Equal Access to Life-Saving Liver Treatment - Sign the Petition Now!
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis).
We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH.
Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference!
🔗 Sign the Petition Here: https://globalliver.salsalabs.org/petitionrezdiffracanada
🔗 Read Our Media Release: Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
Thank you for standing with us in this important cause.
Our Team
Our History
Our History
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our History
Our History
Our History
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 15.5M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
Our Mission
Our History
Our Mission
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with MASLD or MASH by advocating for access to approved treatments and care.
I want to get involved!
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
Collaboration: Global Liver Institute-Liver Action Network
